Laparoscopic Surgery for Inflammatory Bowel Disease: Technical Issues
Points of interest:
burden of Crohn’s disease–1:14
how often do patients require surgery?–1:43
why do patients require surgery?–2:35
how often does refractory disease occur?–3:25
increasing frequency IP/FS disease with time–4:09
appearance of perforating complications–5:02
in which patients do IP/FS complications occur?–5:46
citation–7:35 (provide link: http://www.ncbi.nlm.nih.gov/pubmed/?term=16454844
how often does cancer occur?–7:58
have we made a difference?–9:08
citation–9:25 (provide link: http://www.ncbi.nlm.nih.gov/pubmed/?term=15647188)
the ACCENT 1 randomized trial–10:13 (provide link: http://www.ncbi.nlm.nih.gov/pubmed/12047962)
the ACCENT 2 trial–11:09
clear indications for surgery–11:46
surgical vs percutaneous drainage of intra-abdominal abscess–12:02
inflammatory mass without clear abscess formation case 1–12:49
inflammatory mass without clear abscess formation case 2–14:15
inflammatory mass without clear abscess formation case 3–14:49
natural history of active CD–15:55
when is surgery appropriate?–16:20
Keyword(s): abscess formation, ACCENT 1 randomized trial, ACCENT 2 trial, active CD, anti-TNF biologics, anti-TNF therapy, asymptomatic, bacterial antigen, behavior, biologic therapy, cancer, CBir1, children, chronic intermittent course, classes of agents, cocominantly, cohort, colitis, colonoscopy, colorectal cancer, complicated patients, Copenhagen population database, corticosteroid requirement, Crohns disease, CT scan, develop, diagnosis, diarrhea, disease activity states, dominant antigen, efficacy trial, episodic anti-TNF agent, family history of Crohns disease, female predominance, fever, fistulizing Crohns disease, fistulizing disease, flagelated bacteria, flagellin, France, French group, FS disease, gas, gastroenterologist, GI, higher dose, immune response to bacterial antigen, immunomodulatory therapy, incidence, increasing frequency, indications for surgery, inflammatory mass, Infliximab, intermittent obstructive symptoms, internal perforating disease, intra-abdomiinal penetrating disease, IP, IV antibiotics, leukocytosis, liquid diet, long term remission, maintenance drugs, maintenance of remission, maintenance trial, malignancy, malignant complications, markers, medical approach, medical therapy, medically induced remission, medications, methodical approach, methotrexate, mutliple interloop fistulae, natural history, North America, obstructive symptoms, one year outcome, oscillating disease activity state, outpatient antibiotics, outset, partial SBO symptoms, peak age, penetrating disease, percutaneous drainage of intra-abdominal abscess, perforating complications, perforation, perianal disease, perineal sepsis, peritoneal signs, placebo, population based studies, post diagnosis, post surgical abscess, post-op recurrence, postsurgical remission, predict, Prednisone, presentation, presented, prevalence, radiologically, rapid disease progression, rates of hospitalization, rates of surgery, refractory inflammatory disease, refractory luminal disease, relative risk, resolution, retrospective study, retrospectively, RLQ pain, SB adenocarcinoma, Scandanavian study, scheduled maintenance infusions, serological immune responses, serological markers, serum, small bowel cancer, small bowel xrays, steroids, stricturing disease, studies, subanalysis, surgical cases, surgical consultation, surgical treatment, Sweden, symptomatic fibrostenosing disease, symptomatic fibrotic strictures, thyopurines, topically active budesonide, UC, variables, weight loss, young onset
